|
Today, over 10 million individuals have or are at risk of osteoporosis—80% are women. Almost 34 million more have low bone mass, placing them at increased risk for osteoporosis. With estrogen treatment running into controversy, there is now competition between two drugs to treat osteoporosis- Fosamax and Actonel.
Osteoporosis treatment is a hotly debated area in medicine. There’s been the concern over using estrogen, which protects bone but has side effects such as heart attack and cancer risk. Now, there’s this- the latest research focusing on two popular osteoporosis medicines has come up with a conclusion as to which is best, and the results are creating a bit of a controversy.
According to findings of the Fosamax-Actonel comparison trial, in fact the first U.S. head-to-head study comparing FDA approved once weekly osteoporosis treatments in postmenopausal women with osteoporosis, Fosamax provided greater increases in bone mineral density at all body sites, especially at the hip. In fact, Fosamax was as much as 84% more effective in increasing bone density than Actonel in certain locations.
Osteoporosis is a disease that causes bones to become more porous, gradually making them weaker and more brittle, and thus, more likely to fracture. Both Fosamax and Actonel are in the group of medications called bisphosphanates. They act to block bone reuptake, and thus, prevent thinning, and even cause an increase in bone density.
But the question is, which is more significant? Whether a drug can increase bone density or whether a drug can affect the true bottom line i.e. decreasing one’s risk of fracture? "When you get a bone density report it really only measures bone density. It doesn’t measure bone quality and more than likely bone quality is more important than bone density", says Dr. Paula Rackoff, Chief of Rheumatology at Beth Israel Medical Center in New York. She is like many experts who would say what one is really concerned about is the risk of fracture.
If any particular company wants the million dollar answer, they’ll have to do the head to head study on fracture risk. Until then, Dr. Rackoff believes that doctors should keep patients on the medicine they’re on right now. But hers is just one opinion in what is a very unclear situation. "I think the biggest message is that people need to pay attention to osteoporosis and there are two very good drugs that can reduce your fracture risk. If I really had to stretch and had someone with extremely low bone density I might give Fosamax over Actonel. But they both have very good fracture data", states Dr. Rackoff.
In individual studies on each drug, both showed about a 50% decrease in fracture risk, but again, the studies were independent of the other drug and did not look at them head to head. And overall, side effects are about the same with both Fosamax and Actonel, according to the research. For more information, click here: www.nof.org/
|
What is Gastroenterology?
Video: Dr. Jonathan Cohen of the Concorde Medical Group discusses Gastroenterology. Gastroenterology is a specialized field of medicine that focuses on the digestive tract - from the mouth to the anus. Gastroenterolgy studies the functioning and disorders of the esophagus, stomach and intestines, as well as its associated organs such as the liver, pancreas and gall bladder. There is documented evidence that some forms of Gastroenterolgy were practiced in ancient Egypt. Greek, Roman and Arab practitioners studied the digestive tracts of the human body with specially designed spatula and mirrors illuminated by candles or oil lamps. More complex tools for examining the rectum with dilating specula were found in the ruins of Pompeii.
(Read more)Saving Bone Cancer Patients' Limbs
Bone cancer is rare, but up till recently if it was diagnosed in a limb, it almost certainly meant an amputation. But that has changed with the advent of internal prosthetics that can replace the diseased bone. Surgeons can now reconstruct a bone with prosthetics if a malignancy is not wrapped around blood vessels. Dr. James Wittig of New York City's Mt. Sinai Medical Center says that, these days, 95 percent of patients with bone sarcomas, which comprise less than 1 percent of all cancers, can have their limbs saved. But some bone cancer sufferers may still be having amputations due to ignorance of the technology.
(Read more)Hormone Stimulates Bone Stem Cells, May Reverse Osteoporosis
A hormone naturally produced in the body seems to stimulate stem cells to promote bone growth, a recent study revealed. The findings may hold hope for developing new treatments for osteoporosis, a disorder in which the bones lose calcium and become dangerously brittle, especially in older people. The condition affects one in four women over the age of 50, according to the World Health Organization. The experiment with the hormone, known as interferon gamma, is discussed in a paper published in the journal Stem Cells, and was performed by scientists at the Aging Bone Research Center of the University of Sydney’s Nepean Clinical School, and the Research Institute of the McGill University Health Center.
(Read more) |